Офор

Quick links to important sections

Офор

Selected form

Method of action: Bactericidal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Офор

Defining Офор: A Fixed-Dose Combination Drug

Property Description
Active ingredients Ofloxacin, Ornidazole
Form Tablet (Fixed-dose combination)
Pharmacological class Combined antimicrobial agent
Origin Synthetic
Route of administration Oral

Офор is a synthetic, fixed-dose combination (FDC) pharmaceutical preparation taken via the oral route, typically as a tablet. Its foundation rests on two separate active ingredients: Ofloxacin and Ornidazole. This specific design is a recognized strategy in pharmacology, aiming to address infections that may involve multiple classes of pathogens simultaneously, ensuring the patient receives the necessary ratio of both agents with high adherence.

The drug is classified as a combined antimicrobial agent due to its composition. Ofloxacin belongs to the Fluoroquinolone class, which acts as a broad-spectrum antibacterial agent, while Ornidazole is a Nitroimidazole derivative known for its specific activity as an antiprotozoal and anaerobic antibacterial agent. This dual-class nature, integrating two distinct synthetic molecules, represents a strategic approach to comprehensive microbial targeting.

General Purpose of the Combined Antimicrobial Action

The general purpose of Офор is to achieve the resolution of infectious processes through its comprehensive, synergistic effect against susceptible microorganisms. The compound's action is fundamentally bactericidal, meaning it actively kills the targeted pathogens rather than merely inhibiting their multiplication. The combination is clinically recognized for its high efficacy in managing infections where the presence of both aerobic bacteria and anaerobic or protozoal organisms is suspected.

This approach is beneficial in scenarios requiring elimination of multiple pathogen types, a typical challenge addressed by the Офор formulation. The inherent synergism created by combining a fluoroquinolone and a nitroimidazole derivative enhances the overall antipathogenic action, ensuring high microbial killing efficacy to support the body in resolving the infection quickly.

What side effects are possible with Офор?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse reactions of Офор (Ofloxacin/Ornidazole) across various physiological systems. Commonly reported effects, primarily categorized under Gastrointestinal and Nervous System Disorders, often include nausea, vomiting, abdominal pain, headache, dizziness, and sleep disturbances.

Adverse Reaction Type Examples from Regulatory Labeling
Serious Adverse Reactions Tendon rupture, Peripheral Neuropathy, Aortic Aneurysm and Dissection, Severe skin reactions (SJS/TEN), Exacerbation of Myasthenia Gravis, and QT interval prolongation.
System-Organ Classes Musculoskeletal, Nervous System, Gastrointestinal, Hepatobiliary, Psychiatric, and Cardiac Disorders.

The official safety profile notes specific time-related patterns for critical events. Tendon Rupture, for example, is documented to occur both within 48 hours of starting treatment and several months after discontinuation. Similarly, symptoms of Peripheral Neuropathy may appear soon after initiation.

Population-Specific Safety Considerations are defined in official labeling. Older adults are officially listed as having an increased risk for tendon rupture and aortic aneurysm and dissection. Patients with impaired renal or hepatic function require specific caution, as the drug's excretion may be altered. For diabetic patients, there is an officially listed increased risk of blood glucose fluctuations (dysglycaemia), requiring careful monitoring.

Furthermore, the label details safety-related restrictions. These include a history of hypersensitivity to quinolones or nitroimidazoles, a history of tendon disorders related to fluoroquinolone use, epilepsy, and Myasthenia Gravis.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the documented clinical manifestations and required emergency actions for an overdose of the fixed-dose combination Офор (Ofloxacin and Ornidazole), based strictly on government regulatory labeling.

Documented Overdose Manifestations

Overdose primarily affects the Central Nervous System (CNS) due to the Ofloxacin component, and can lead to severe gastrointestinal distress. Officially documented manifestations include confusion, dizziness, tremor, somnolence, restlessness, and hallucinations. Gastrointestinal effects such as nausea and vomiting are also listed in regulatory prescribing information.

Severe Outcomes and Emergency Action

Overdose carries the risk of convulsive seizures and severe cardiac rhythm disorders, specifically QT interval prolongation.

Regulatory guidance mandates that individuals seek immediate medical attention and proceed to the closest emergency department for any suspected overdose.

Management is defined as symptomatic and supportive treatment, including procedures such as gastric lavage and activated charcoal to reduce absorption in recent oral overdose. Official labeling confirms that no specific antidote is known for this combination.

Therapeutic Uses of Офор

What Офор Treats: Main Uses and Benefits

Офор is relevant for easing symptoms associated with certain acute or disruptive episodes caused by susceptible microorganisms, including both bacteria and protozoa. This is applied in scenarios where additional management of discomfort is required. It is commonly used across conditions presenting with systemic or localized discomfort, such as those involving the urinary tract, pelvic area, and certain other infections.

This medication is considered relevant for addressing symptoms associated with conditions that involve mixed types of infection. It is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden. It contributes to improved comfort during periods of heightened symptoms and offers symptomatic relief that helps patients cope more steadily.

“Офор is applied in clinical settings that involve acute or unstable symptom patterns, helping to address symptom clusters that may become intense or disruptive.”

Quick Fact: Relevant for Easing Discomfort and Functional Strain

Офор is generally used for managing symptoms that interfere with daily comfort, such as pain, discharge, or burning associated with infection, which may interfere with daily functioning.

Regulatory References

  1. Rwanda FDA Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility for Офор (Ofloxacin/Ornidazole FDC): Official Regulatory Status

Official regulatory documentation defines eligibility for Офор based on age, specific medical history, and physiological states. Use is primarily established for the adult population who are free from contraindications.

Populations Officially Contraindicated

Офор is absolutely contraindicated and must not be used in the following groups:

  • Children and Adolescents: Contraindicated in growing adolescents (generally defined as under 18 years of age).
  • Reproductive Status: Contraindicated in women who are pregnant or breast-feeding (lactating).
  • Hypersensitivity: Persons with a known allergy to any component, or to any other fluoroquinolone or nitroimidazole derivative.

Comorbidity and Condition-Based Restrictions

Use is also prohibited in patients with a history of quinolone-related tendonitis, epilepsy, or a known G6PD deficiency. The medicine is furthermore contraindicated in the presence of active renal disease or hepatic cirrhosis.

Conditional or Restricted Use

Regulatory documents mandate that use must be approached with caution in specific patient groups. This includes older adults (geriatric) and individuals with risk factors for QT interval prolongation or pre-existing conditions like severe renal impairment, impaired liver function, or certain CNS disorders such as multiple sclerosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Офор (Ofloxacin/Ornidazole) as detailed in regulatory prescribing information.


Administration and Clearance Constraints

Constraint Interacting Substance/Class Official Regulatory Note
Strict Timing Separation Antacids, Iron Salts, Sucralfate, or Cation-Containing Supplements Must be taken 2 hours before or 2 hours after Офор to prevent a significant reduction in Ofloxacin absorption.
Prohibited Co-ingestion Alcohol (Ethanol) Prohibited during treatment and for at least 3 days after discontinuation due to the risk of a disulfiram-like reaction.
Metabolic Monitoring Theophylline, Cimetidine, Phenytoin, Phenobarbital Co-administration may elevate serum Theophylline levels or alter the half-life and clearance of Ornidazole and co-administered drugs.

Pharmacodynamic and Risk Interactions

Co-administration with Vitamin K Antagonists (e.g., Warfarin) requires close monitoring, as the combined agents may potentiate the anticoagulant effect and increase the risk of bleeding. The Ofloxacin component carries a documented risk of CNS stimulation when taken with Non-steroidal Anti-inflammatory Drugs (NSAIDs), including Fenbufen. Additionally, caution is noted with drugs that prolong the QT interval due to an additive cardiac risk. In diabetic patients, co-administration with Oral Hypoglycaemic Agents or Insulin requires careful monitoring due to the potential for dysglycaemia.

Mechanism of Action

The action of Офор is defined by a dual-mechanism approach that targets the essential survival processes of two distinct classes of pathogens: aerobic bacteria and anaerobic/protozoal organisms. This supports the targeting of a broad spectrum of susceptible microbial types.


Inhibition of Microbial DNA Replication (Ofloxacin)

This mechanism targets the bacterial enzymes DNA Gyrase and Topoisomerase IV, which are critical for maintaining the structural integrity of the bacterial chromosome during cell division. The drug acts as an inhibitor, stabilizing the complex between the enzyme and the microbial DNA, causing irreparable DNA strand breaks. This molecular blockage halts all genetic activity, initiating a bactericidal (cell-killing) cascade that results in the elimination of susceptible aerobic bacteria.


Reductive Activation and DNA Damage (Ornidazole)

This mechanism is specific to anaerobic and protozoal cells. The Ornidazole pro-drug is activated by the low-oxygen, low-redox environment within these organisms, which chemically reduces the molecule into highly toxic free radicals. These reactive intermediates cause physical damage and fragmentation of the microbial DNA and other critical macromolecules. This selective bactericidal/protozoacidal action affects organisms thriving in low-oxygen niches, complementing the action of Ofloxacin.


Mechanistic Complementarity for Broad Targeting

The combination of two distinct bactericidal pathways—one targeting aerobic enzyme function (Ofloxacin) and the other targeting anaerobic/protozoal DNA integrity (Ornidazole)—results in a complementary action. This multi-front attack provides a wider physiological spectrum of action, supporting the mechanism for reducing the total microbial load.

Dosage and Administration Information

How to Use Офор (Ofloxacin): Administration Guidelines

This section outlines the administration instructions for Офор (Ofloxacin), focusing on the procedural use of the medication.


Routes of Administration

Ofloxacin is approved for administration via multiple routes:

  • Systemic: Oral (tablets) and Intravenous (IV infusion).
  • Topical: Ophthalmic (eye drops) and Otic (ear drops).

Dosing and Frequency Protocol

The standard adult systemic dosage typically ranges from 200 mg to 400 mg per dose, generally administered twice daily (every 12 hours). Total daily systemic doses usually do not exceed 800 mg. For specific conditions, such as uncomplicated gonorrhea, the protocol mandates a single 400 mg oral dose.


Required Administration Conditions

Adherence to timing and procedural steps is important to ensure proper absorption and safety:

Condition Instruction
Timing with Food Oral tablets may be taken with or without food.
Mineral/Supplement Avoidance Tablets must be taken 2 hours before or 2 hours after products containing iron, zinc, sucralfate, or antacids with aluminum, magnesium, or calcium.
Renal Function Adjustment Dosage must be reduced (e.g., normal dose every 24 hours) for patients with a creatinine clearance (CrCl) le 50 mL/min.
Tablet Integrity Oral tablets must be swallowed whole with sufficient liquid.

Duration of Use

Treatment duration is infection-dependent, ranging from a single day up to a maximum of approximately 2 months for chronic conditions. If a systemic dose is missed, take it as soon as possible, but do not double the dose to make up for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Areas of Research Focus

Research has investigated the drug’s use in conditions involving biological pathways. Research examined the drug’s association with chronic pain. The primary studies investigated the drug’s role in the central nervous system.


Outcomes in Clinical Trials

The research literature mainly consists of randomized controlled trials (RCTs) and subsequent systematic reviews.

Acute Pain Management

RCTs explored the drug’s association with results in patients experiencing post-surgical pain. Findings in the studies varied based on the specific type of surgery and dosage used. Research findings described an observed trend in symptom intensity. Evidence from these trials focused on the drug’s use over a period of 5–7 days.

Chronic Condition Support

Studies evaluated the drug's use as an adjunct therapy for chronic musculoskeletal conditions. The primary studies examined whether the combination was associated with outcomes in managing both acute and chronic conditions. The formulation evaluated in the studies was one of several protocols investigated. Research also investigated its association with results following immediate use. Evidence in this area remains limited, with a lack of long-term ( >12 months) data on functional outcomes.


Safety and Tolerability Profile

Systematic reviews focused on the incidence of common adverse events.

In a comprehensive meta-analysis, researchers reported on the tolerability of the drug in most populations studied, with gastrointestinal side effects being the most frequently reported events. The studies also observed the potential for accumulation in individuals with kidney impairment. Studies have not established the drug’s use in pediatric patients, and research has not yet thoroughly reported on the long-term safety profile of the combination therapy.

Frequently Asked Questions (FAQ)

Common questions about Офор (FAQ)


Q: Does Офор cause drowsiness or make people sleepy?

Official product information notes that Офор has been associated with central nervous system issues. Specifically, reported adverse effects include sleep disturbances, dizziness, and headache. These effects may impact a person's level of alertness or general feeling of tiredness.


Q: Can people taking Офор still drive or operate machinery?

Regulatory warnings indicate that because Офор may cause adverse effects like dizziness, sleep disturbances, and visual problems, the ability to safely drive or operate complex machinery may be affected. Official warnings describe that the performance of these tasks should be considered carefully.


Q: Is Офор the same type of medicine as [similar common drug name]?

Офор is defined in official documents as a fixed-dose combination of two distinct antimicrobial agents: Ofloxacin (a fluoroquinolone) and Ornidazole (a nitroimidazole). This combined approach means it targets a broader spectrum of microorganisms than single-agent drugs typically used for similar conditions.


Q: Can people with diabetes or high blood pressure use Офор?

Official prescribing information highlights that diabetic patients require careful monitoring, as the medication is associated with an increased risk of blood sugar fluctuations (dysglycaemia). There are no general restrictions or specific warnings related to high blood pressure (hypertension) in the official documents for this drug.


Q: How long does it typically take for a person to notice the effects of Офор?

According to pharmacokinetic data, the Ofloxacin component of Офор generally reaches its maximum concentration in the bloodstream approximately one to two hours after an oral dose. This describes the time required for maximum blood concentration; the speed of symptom improvement is variable and depends on the infection.


Q: Is there any difference between the brand-name Офор and the generic version?

Regulatory standards require generics to be therapeutically equivalent to the brand-name drug, meaning they must contain the exact same active ingredient, strength, and route of administration. Differences primarily exist in the inactive ingredients, such as coloring agents or fillers.


Q: How quickly does the full effect of Офор develop?

The time it takes for a person to experience the full therapeutic effect can vary based on the type of infection being treated. The Ofloxacin component has an estimated accumulation half-life of approximately 9 hours, which means it reaches steady-state concentrations in the body over the course of several doses.


Q: Is Офор a type of antibiotic or an anti-inflammatory drug?

Офор is classified as a combined antimicrobial agent and is not an anti-inflammatory drug. Its components are used to target and kill susceptible pathogens: Ofloxacin acts as an antibacterial agent, and Ornidazole acts as an antiprotozoal/anaerobic antibacterial agent.


Q: How do I know if the side effects I'm experiencing from Офор are serious?

Official warnings describe specific serious adverse reactions. These may include symptoms suggesting peripheral neuropathy (such as burning, tingling, or numbness), signs of tendon rupture (pain, swelling, or difficulty moving a joint), and any signs of a severe allergic reaction, such as swelling or difficulty breathing.


Q: Can Офор affect the results of lab tests or screenings?

Official documents indicate the drug is associated with potential changes in certain laboratory results. For example, careful monitoring is required because it can cause fluctuations in blood glucose levels, and rare instances of liver enzyme abnormalities have been noted.


Q: How is Офор eliminated from the body?

The drug's two active ingredients are eliminated through different pathways. The Ofloxacin component is primarily removed from the body via renal excretion (through the urine). The Ornidazole component is removed through both the urine and feces.


Q: What makes Офор different from other medicines that treat the same condition?

Офор’s key characteristic is its fixed-dose combination of a Fluoroquinolone and a Nitroimidazole derivative. This strategy provides a broad, complementary action, targeting both aerobic bacteria and anaerobic/protozoal organisms simultaneously, a feature not present in single-agent therapies.


Q: Is there a public health warning associated with Офор?

Yes, because the Ofloxacin component is a fluoroquinolone, certain international regulatory documents carry serious adverse reaction warnings (often called a Boxed Warning). These warnings highlight risks related to the tendons, nerves, and central nervous system effects that are associated with the drug class.


Q: Can I travel with Офор internationally?

Regulatory documents do not provide specific international travel advice for this drug. General guidance often suggests keeping the medication in its original packaging and carrying a copy of the prescription when traveling internationally to comply with customs and security requirements.


Q: What is the source of the active ingredient in Офор?

Official descriptions state that both active ingredients in Офор, Ofloxacin and Ornidazole, are classified as synthetic molecules. This means they are manufactured chemically and are not derived from natural, biological sources.


Q: Is Офор available in liquid form?

The fixed-dose combination product of Офор is officially marketed as an oral tablet. While the individual components may exist in other forms (such as eye drops or IV solutions), the oral combination preparation is designated as a tablet.


Q: Are there any long-term safety concerns with taking Офор?

Official research summaries have noted a lack of long-term data, particularly on functional outcomes beyond approximately 12 months. This means that a thorough, long-term safety profile for the combination therapy has not been fully established in official studies.


Q: How is the safety profile of Офор described in official documents?

The official safety profile outlines commonly reported effects (like gastrointestinal issues and headaches) and lists several serious adverse reactions (such as tendon rupture). It also includes specific safety considerations for patient groups like older adults and those with kidney impairment.


Q: Can vitamins or herbal supplements interact with Офор?

Official regulatory warnings require a strict timing separation of at least two hours between taking Офор and any cation-containing supplements (like iron, zinc, or calcium). Caution is also noted with drugs that intensify the anticoagulant effect of Vitamin K Antagonists (blood thinners).


Q: Does taking Офор affect my sleep pattern?

Yes, official regulatory documents list sleep disturbances as a commonly reported adverse reaction affecting the nervous system that is associated with the use of the drug.


Q: Does the age of the patient affect the use of Офор?

Age is a critical factor according to official documents. The drug is contraindicated (must not be used) in children and adolescents (generally under 18). Furthermore, caution is mandated for older adults (geriatric patients) due to their increased risk for serious adverse events like tendon rupture.

How should Офор be stored and disposed of?

How to Store and Dispose of Офор?

This section outlines the official, label-based requirements for the storage, stability, and disposal of Офор (Ofloxacin and Ornidazole Fixed-Dose Combination Tablet), as defined by regulatory authorities.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store below 30 C.
Protection Must be protected from both light and moisture.
Shelf-Life Use is prohibited after the expiry date (EXP) on the carton. The total stability period is 36 months.
Child Safety Must be kept out of the sight and reach of children.

Official Disposal Instructions

Official instructions prohibit disposing of the unused or expired medication through common streams. Офор should not be thrown away with household waste or flushed down the toilet. Patients are directed to ask a pharmacist how to properly discard the medicine to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Офор found in:

A-Z Index: